Patient derived organoids for the investigation of therapeutic agents
Research type
Research Study
Full title
Patient derived organoids for the investigation of therapeutic agents
IRAS ID
284699
Contact name
Kourosh Saeb-Parsy
Contact email
Sponsor organisation
Avatrial Ltd
Duration of Study in the UK
10 years, 0 months, 1 days
Research summary
Availability of clinically-relevant experimental models to investigate the safety and efficacy of novel therapeutic agents to treat disease remains an urgent unmet need. Increased understanding of disease has led to the discovery of new disease subtypes as well as calls for new therapeutics that can treat historically untreatable diseases. Despite tremendous advances of drug testing through the use of traditional cell culture and animal models, existing technologies either do not faithfully recapitulate disease or are too costly to scale up for general applications. 3D expanded patient-derived organoid technology enables propagation of cells from both diseased and healthy tissue whilst maintaining the tissue characteristics to a higher degree than previously achieved. Avatrial Ltd. aims to utilize this novel technology to generate 3D organoid cell cultures from fresh healthy and diseased human tissue. These models will be used to assess the safety, toxicity and efficacy of therapeutic agents both in vitro and in vivo. The research will be conducted by Avatrial Ltd, a spin-out company from the University of Cambridge, founded by scientists from the University of Cambridge.
REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
20/EM/0147
Date of REC Opinion
9 Jul 2020
REC opinion
Further Information Unfavourable Opinion